The recent FDA approval of the use of esketamine for treatment-resistant depression means many Americans suffering will soon find relief. The drug, Spravato, was approved for patients who have failed to respond at all to at least two other antidepressant medications. After years of clinical trials, the decision to officially approve Spravato took a month before a panel of experts voted in favor of the new treatment. Since treatment-resistant depression plagues so many among us, this new treatment has generated tremendous hope for depression sufferers, their loved ones, and their mental health clinicians.
In an exciting development, Regional Anesthesia and Pain Medicine published the first set of guidelines for the use of ketamine for treating pain—a framework for doctors and institutions, who should get it, and who should not. Ketamine infusions have emerged as a leading option for the treatment of both chronic and acute pain. Some chronic pain patients report a reduction in pain symptoms for up to six months post-infusion. The World Health Organization lists ketamine as an essential medicine, primarily for its analgesic qualities.
Ketamine has earned its clout as one of the most effective treatments for depression, bipolar disorder and PTSD currently available on the market. However, ketamine is also effective in pain management, specifically for the treatment of chronic pain conditions, such as CRPS, migraine headaches and as a fibromyalgia treatment. Pain is the #1 cause of physical disability in the world, but modern pain management options – including opiates and other medications, physical therapy, meditation, acupuncture and other complimentary and alternative techniques – tend to treat pain symptoms as they continue to occur, rather than stopping the pain from reoccurring altogether.